Bibliografia articolo depressione

image_pdfimage_print

Le basi farmacologiche della terapia: il Manuale. Goodman&Gilman II ed. Laurence L Bruton, Randa Hilal-Dandan

Farmacologia: principi di base e applicazioni terapeutiche,edizione minerva medica, F.Rossi, V. Cuomo, C. Riccardi

Mild to moderate antenatal unipolar depression: Treatment; Uptodate Sophie Grigoriadis

Postpartum blues and unipolar depression: Prevention and treatment Uptodate Peter, P Roy-Byrne

Unipolar depression in adults and initial treatment: General principles and prognosis, Uptodate Gregoy Simon

Unipolar depression in adults: Continuation and maintenance treatment, Uptodate, Robin B Jarret

Unipolar depression in adults: Treatment with second­generation antipsychotics, Uptodate  Craig Nelson

Unipolar major depression in adults: Choosing initial treatment Uptodate Gregory Simon

Vortioxetine: A New Antidepressant Choice in the United States Christoph U. Correll, MD American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.

Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004 Jul. 61(7):714-9. [Medline].

Ishak WW, Ha K, Kapitanski N, Bagot K, Fathy H, Swanson B, et al. The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression. Harv Rev Psychiatry. 2011 Dec. 19(6):277-89. [Medline].

Hollon SD, Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. Depress Anxiety. 2010 Oct. 27(10):891-932. [Medline][Full Text].

David-Ferdon C, Kaslow NJ. Evidence-based psychosocial treatments for child and adolescent depression. J Clin Child Adolesc Psychol. 2008 Jan. 37(1):62-104. [Medline].

APA. Practice Guideline for the Treatment of Patients with Major Depressive Disorder (3rd edition). Accessed May 3, 2011. American Psychiatric Association. [Full Text].

Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007 Mar. 64(3):327-37. [Medline].

Alexopoulos GS. Depression in the elderly. Lancet. 2005 Jun 4-10. 365(9475):1961-70. [Medline].

Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry. 1999 May. 156(5):675-82. [Medline].

Kempton MJ, Salvador Z, Munafò MR, Geddes JR, Simmons A, Frangou S, et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry. 2011 Jul. 68(7):675-90. [Medline].

Sacher J, Neumann J, Fünfstück T, Soliman A, Villringer A, Schroeter ML. Mapping the depressed brain: A meta-analysis of structural and functional alterations in major depressive disorder. J Affect Disord. 2011 Sep2. [Medline].

Rice F. Genetics of childhood and adolescent depression: insights into etiological heterogeneity and challenges for future genomic research. Genome Med. 2010 Sep 20. 2(9):68. [Medline][Full Text].

Tsuang MT, Faraone SV. The genetics of mood disorders. Baltimore, MD: Johns Hopkins University Press, 1990.

Abkevich V, Camp NJ, Hensel CH, Neff CD, Russell DL, et al. Predisposition locus for major depression at chromosome 12q22-12q23.2. Am J Hum Genet. 2003 Dec. 73(6):1271-81. [Medline][Full Text].

Holmans P, Zubenko GS, Crowe RR, DePaulo JR Jr, Scheftner WA, Weissman MM, et al. Genomewide significant linkage to recurrent, early-onset major depressive disorder on chromosome 15q. Am J Hum Genet. 2004 Jun. 74(6):1154-67. [Medline][Full Text].

Lohoff FW. Overview of the genetics of major depressive disorder. Curr Psychiatry Rep. 2010 Dec. 12(6):539-46. [Medline][Full Text].

Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003 Jul 18. 301(5631):386-9. [Medline].

Zhang X, Gainetdinov RR, Beaulieu JM, Sotnikova TD, Burch LH, Williams RB, et al. Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron. 2005 Jan 6. 45(1):11-6. [Medline].

Garriock HA, Allen JJ, Delgado P, Nahaz Z, Kling MA, Carpenter L, et al. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry. 2005 Nov. 10(11):976-7. [Medline].

Yamada K, Hattori E, Iwayama Y, Ohnishi T, Ohba H, Toyota T, et al. Distinguishable haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B with female major depression. Biol Psychiatry. 2006 Jul 15. 60(2):192-201. [Medline].

Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Pütz B, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004 Dec. 36(12):1319-25. [Medline].

Akiskal HS, Weller ES. Mood disorders and suicide in children and adolescents. In: Kaplan HI, Saddock BJ, eds. Comprehensive Textbook of Psychiatry. 5th ed. Lippincott Williams & Wilkins; 1989. Vol 2:

Weissman MM, Leckman JF, Merikangas KR, Gammon GD, Prusoff BA. Depression and anxiety disorders in parents and children. Results from the Yale family study. Arch Gen Psychiatry. 1984 Sep. 41(9):845-52. [Medline].

Nobile M, Begni B, Giorda R, Frigerio A, Marino C, Molteni M, et al. Effects of serotonin transporter promoter genotype on platelet serotonin transporter functionality in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999 Nov. 38(11):1396-402. [Medline].

Birmaher B, Kaufman J, Brent DA, Dahl RE, Perel JM, al-Shabbout M, et al. Neuroendocrine response to 5-hydroxy-L-tryptophan in prepubertal children at high risk of major depressive disorder. Arch Gen Psychiatry. 1997 Dec. 54(12):1113-9. [Medline].

Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci. 2003 Mar. 58(3):249-65. [Medline].

Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24. 57(2):203-9. [Medline].

Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology. 2006 Oct. 31(10):2281-8. [Medline].

McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006 May. 78(5):804-14. [Medline][Full Text].

Bruce ML. Psychosocial risk factors for depressive disorders in late life. Biol Psychiatry. 2002 Aug 1. 52(3):175-84. [Medline].

O’Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol. 1984 May. 93(2):158-71. [Medline].

Abramson, Lyn Y.; Metalsky, Gerald I.; Alloy, Lauren B. Hopelessness Depression: A Theory-Based Subtype of Depression. Psychol Rev. Apr 1989. Vol 96(2):358-372.

Hyde JS, Mezulis AH, Abramson LY. The ABCs of depression: integrating affective, biological, and cognitive models to explain the emergence of the gender difference in depression. Psychol Rev. 2008 Apr. 115(2):291-313. [Medline].

Lewinsohn, P. M. A behavioral approach to depression. Friedman R.J. and Katz M.M. The psychology of depression: Contemporary theory and research. Washington, DC.: Winston-Wiley; 1974. 157-178.

Ferster, C. B. A functional analysis of depression. Am Psychol. 1973. 28, 857-870.

Martell, C. R., Addis, M. E., & Jacobson, N. S. Depression in context: Strategies for guided action. New York: Norton; 2001.

Frodl T, Reinhold E, Koutsouleris N, Donohoe G, Bondy B, Reiser M, et al. Childhood stress, serotonin transporter gene and brain structures in major depression. Neuropsychopharmacology. 2010 May. 35(6):1383-90. [Medline][Full Text].

Karg K, Burmeister M, Shedden K, Sen S. The Serotonin Transporter Promoter Variant (5-HTTLPR), Stress, and Depression Meta-analysis Revisited: Evidence of Genetic Moderation. Arch Gen Psychiatry. 2011 May. 68(5):444-54. [Medline].

De Bellis MD, Dahl RE, Perel JM, Birmaher B, al-Shabbout M, Williamson DE, et al. Nocturnal ACTH, cortisol, growth hormone, and prolactin secretion in prepubertal depression. J Am Acad Child Adolesc Psychiatry. 1996 Sep. 35(9):1130-8. [Medline].

Krishnan KR. Biological risk factors in late life depression. Biol Psychiatry. 2002 Aug 1. 52(3):185-92. [Medline].

Hammen C, Burge D, Adrian C. Timing of mother and child depression in a longitudinal study of children at risk. J Consult Clin Psychol. 1991 Apr. 59(2):341-5. [Medline].

Wickramaratne P, Gameroff MJ, Pilowsky DJ, Hughes CW, Garber J, Malloy E, et al. Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry. 2011 Jun. 168(6):593-602. [Medline].

Thomas AJ, Kalaria RN, O’Brien JT. Depression and vascular disease: what is the relationship?. J Affect Disord. 2004 Apr. 79(1-3):81-95. [Medline].

Klerman GL. The current age of youthful melancholia. Evidence for increase in depression among adolescents and young adults. Br J Psychiatry. 1988 Jan. 152:4-14. [Medline].

Gershon ES, Hamovit JH, Guroff JJ, Nurnberger JI. Birth-cohort changes in manic and depressive disorders in relatives of bipolar and schizoaffective patients. Arch Gen Psychiatry. 1987 Apr. 44(4):314-9. [Medline].

Current depression among adults—United States, 2006 and 2008. MMWR Morb Mortal Wkly Rep. 2010 Oct 1. 59(38):1229-35. [Medline].

Helgason T. Epidemiology of mental disorders in Iceland. A psychiatric and demographic investigation of 5395 Icelanders. Acta Psychiatr Scand. 1964. 40:SUPPL 173:1+. [Medline].

Jablensky A, Sartorius N, Gulbinat W, Ernberg G. Characteristics of depressive patients contacting psychiatric services in four cultures. A report from the who collaborative study on the assessment of depressive disorders. Acta Psychiatr Scand. 1981 Apr. 63(4):367-83. [Medline].

Murphy JM, Laird NM, Monson RR, Sobol AM, Leighton AH. Incidence of depression in the Stirling County Study: historical and comparative perspectives. Psychol Med. 2000 May. 30(3):505-14. [Medline].

Copeland JR, Beekman AT, Dewey ME, Hooijer C, Jordan A, Lawlor BA, et al. Depression in Europe. Geographical distribution among older people. Br J Psychiatry. 1999 Apr. 174:312-21. [Medline].

Kashani JH, Sherman DD. Childhood depression: Epidemiology, etiological models, and treatment implications. Integr Psychiatry. 1988. 6:1-8.

Lewinsohn PM, Hops H, Roberts RE, Seeley JR, Andrews JA. Adolescent psychopathology: I. Prevalence and incidence of depression and other DSM-III-R disorders in high school students. J Abnorm Psychol. 1993 Feb. 102(1):133-44. [Medline].

Garrison CZ, Waller JL, Cuffe SP, McKeown RE, Addy CL, Jackson KL. Incidence of major depressive disorder and dysthymia in young adolescents. J Am Acad Child Adolesc Psychiatry. 1997 Apr. 36(4):458-65. [Medline].

Hankin BL, Abramson LY, Moffitt TE, Silva PA, McGee R, Angell KE. Development of depression from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study. J Abnorm Psychol. 1998 Feb. 107(1):128-40. [Medline].

Siegel JM, Aneshensel CS, Taub B. Adolescent depressed mood in a multiethnic sample. J Youth Adolesc. 1998. 27.

Tohen M, Khalsa HM, Salvatore P, et al. Two-year outcomes in first-episode psychotic depression The McLean-Harvard first-episode project. J Affect Disord. 2012 Jan. 136(1-2):1-8. [Medline].

Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. AACAP. J Am Acad Child Adolesc Psychiatry. 1998 Oct. 37(10 Suppl):63S-83S. [Medline].

Pine DS, Cohen E, Cohen P, Brook J. Adolescent depressive symptoms as predictors of adult depression: moodiness or mood disorder?. Am J Psychiatry. 1999 Jan. 156(1):133-5. [Medline].

Lespérance F, Frasure-Smith N. Depression and heart disease. Cleve Clin J Med. 2007 Feb. 74 Suppl 1:S63-6. [Medline].

Millard PH. Depression in old age. Br Med J (Clin Res Ed). 1983 Aug 6. 287(6389):375-6. [Medline][Full Text].

Alexopoulos GS, Chester JG. Outcomes of geriatric depression. Clin Geriatr Med. 1992 May. 8(2):363-76. [Medline].

Geda YE, Knopman DS, Mrazek DA, Jicha GA, Smith GE, Negash S, et al. Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol. 2006 Mar. 63(3):435-40. [Medline].

Modrego PJ, Ferrández J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol. 2004 Aug. 61(8):1290-3. [Medline].

Katon W, Lyles CR, Parker MM, Karter AJ, Huang ES, Whitmer RA. Association of depression with increased risk of dementia in patients with type 2 diabetes: the diabetes and aging study. Arch Gen Psychiatry. 2012 Apr. 69(4):410-7. [Medline].

Brooks M. Depression accelerates cognitive decline in type 2 diabetes. Medscape Medical News. Available at http://www.medscape.com/viewarticle/812762.. Accessed: October 22, 2013.

Sullivan MD, Katon WJ, Lovato LC, Miller ME, Murray AM, Horowitz KR, et al. Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial. JAMA Psychiatry. 2013 Oct 1. 70(10):1041-7. [Medline].

Li G, Wang LY, Shofer JB, et al. Temporal Relationship Between Depression and Dementia: Findings From a Large Community-Based 15-Year Follow-up Study. Arch Gen Psychiatry. 2011 Sep. 68(9):970-7. [Medline].

Gotlib I, Hammen C. (2002). Handbook of Depression. New York: Guilford Press; 2002:

Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS). Available at http://www.cdc.gov/ncipc/wisqars. Accessed: March 19, 2010.

Conwell Y, Duberstein PR, Caine ED. Risk factors for suicide in later life. Biol Psychiatry. 2002 Aug 1. 52(3):193-204. [Medline].

Elovainio M, Shipley MJ, Ferrie JE, Gimeno D, Vahtera J, Marmot MG, et al. Obesity, unexplained weight loss and suicide: the original Whitehall study. J Affect Disord. 2009 Aug. 116(3):218-21. [Medline].

Friedman RA, Leon AC. Expanding the black box – depression, antidepressants, and the risk of suicide. N Engl J Med. 2007 Jun 7. 356(23):2343-6. [Medline].

Tondo L, Albert MJ, Baldessarini RJ. Suicide rates in relation to health care access in the United States: an ecological study. J Clin Psychiatry. 2006 Apr. 67(4):517-23. [Medline].

Sheikh RM, Weller EB, Weller RA. Prepubertal depression: diagnostic and therapeutic dilemmas. Curr Psychiatry Rep. 2006 Apr. 8(2):121-6. [Medline].Spitz R. Anaclitic depression: An inquiry into the genesis of psychiatric conditions in early childhood. Psychoanalytic Study of the Child. 1946. Vol 2:313-342.

Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987 May. 150:662-73. [Medline].

SIGN. Postnatal Depression and Puerperal Psychosis: A National Clinical Guideline. Scottish Intercollegiate Guidelines Network. 2002. 32.

USPSTF. Screening for depression in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2009 Dec 1. 151(11):784-92. [Medline].

ACOG Committee Opinion No. 343: psychosocial risk factors: perinatal screening and intervention. Obstet Gynecol. 2006 Aug. 108(2):469-77. [Medline].

Peindl KS, Wisner KL, Hanusa BH. Identifying depression in the first postpartum year: guidelines for office-based screening and referral. J Affect Disord. 2004 May. 80(1):37-44. [Medline].

Wisner KL, Parry BL, Piontek CM. Clinical practice. Postpartum depression. N Engl J Med. 2002 Jul 18. 347(3):194-9. [Medline].

Beck CT. Postpartum depression: it isn’t just the blues. Am J Nurs. 2006 May. 106(5):40-50; quiz 50-1. [Medline].

Imsiragic AS, Begic D, Martic-Biocina S. Acute stress and depression 3 days after vaginal delivery–observational, comparative study. Coll Antropol. 2009 Jun. 33(2):521-7. [Medline].

Scrandis DA, Sheikh TM, Niazi R, Tonelli LH, Postolache TT. Depression after delivery: risk factors, diagnostic and therapeutic considerations. ScientificWorldJournal. 2007 Oct 22. 7:1670-82. [Medline].

Spinelli MG. Antepartum and postpartum depression. J Gend Specif Med. 1998 Oct-Nov. 1(2):33-6. [Medline].

ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008 Apr. 111(4):1001-20. [Medline].

Earls, Marian, MD. Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics. 2010 Nov. 126(5):1032-9. [Medline].

Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Mulrow CD, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002 May 21. 136(10):765-76. [Medline].

Vogelzangs N, Beekman AT, Boelhouwer IG, et al. Metabolic depression: a chronic depressive subtype? findings from the InCHIANTI study of older persons. J Clin Psychiatry. 2011 May. 72(5):598-604. [Medline].

Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002 Jul 17. 288(3):351-7. [Medline].

Luijendijk HJ, van den Berg JF, Hofman A, Tiemeier H, Stricker BH. ß-blockers and the risk of incident depression in the elderly. J Clin Psychopharmacol. 2011 Feb. 31(1):45-50. [Medline].

Portella MJ, de Diego-Adeliño J, Ballesteros J, Puigdemont D, Oller S, Santos B, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry. 2011 Jul. 72(7):962-9. [Medline].

U.S. Preventive Services Task Force. Screening for Depression in Adults. U.S. Preventive Services Task Force. Available at http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/depression-in-adults-screening1. January 26, 2016; Accessed: January 27, 2016.

Mitchell AJ, Coyne JC. Do ultra-short screening instruments accurately detect depression in primary care? A pooled analysis and meta-analysis of 22 studies. Br J Gen Pract. 2007 Feb. 57(535):144-51. [Medline][Full Text].

Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ. 2003 Nov 15. 327(7424):1144-6. [Medline][Full Text].

Tutus A, Kibar M, Sofuoglu S, Basturk M, Gönül AS. A technetium-99m hexamethylpropylene amine oxime brain single-photon emission tomography study in adolescent patients with major depressive disorder. Eur J Nucl Med. 1998 Jun. 25(6):601-6. [Medline].

[Guideline] Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008 Nov 18. 149(10):725-33. [Medline][Full Text].

Chambless, D. L, Baker, M. J., Baucom, D. H., et al. Update on empirically validated therapies, II. Clin Psychol. 1998. 51, 3-16.

Task Force on Promotion and Dissemination of Psychological Procedures. Training in and dissemination of empirically validated psychological treatments. Clin Psychol. 1995. 48, 3-23.

Chambless, D. L., & Hollon, S. D. Defining empirically supported therapies. JCCP. 1998. 66, 7-18.

US Food and Drug Administration. Celexa (citalopram hydrobromide): Drug safety communication – abnormal heart rhythms associated with high doses. Accessed August 24, 2011. [Full Text].

Celexa (citalopram hydrobromide) [package insert]. St. Louis, Missouri: Forest Pharmaceuticals, Inc. August, 2011. Available at [Full Text].

Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012 Jul. 73(7):953-9. [Medline].

Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012 Jun. 15(5):589-600. [Medline][Full Text].

Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi M. A randomized, double-blind, parallel group study comparing the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. Program and abstracts of the 166th Annual American Psychiatric Association Meeting; May 18-22, 2013; San Francisco, California. Poster NR9-02.

Jacobsen PL, Mahableshwarkar AR, Serenko M, Chen Y, Trivedi M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. Program and abstracts of the 166th Annual American Psychiatric Association Meeting; May 18-22, 2013; San Francisco, California. Poster NR9-06.

Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012 Jul. 27(4):215-23. [Medline].

Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol. 2012 Nov. 26(11):1408-16. [Medline].

Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012 Oct. 28(10):1717-24. [Medline].

Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5?mg and 5?mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013 Mar. 29(3):217-26. [Medline].

Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013 Mar. 16(2):313-21. [Medline].

Rush AJ, Trivedi MH, Stewart JW, et al. Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. Am J Psychiatry. 2011 Jul. 168(7):689-701. [Medline].

Rexulti (brexpiprazole) [package insert]. Rockville, MD: Otsuka America Pharmaceutical, Inc. July 2015. Available at [Full Text].

Agency for Healthcare Research and Quality. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Accessed March 22, 2010. AHRQ: Agency for Healthcare Research and Quality. [Full Text].

Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, et al. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. J Clin Psychiatry. 2011 Oct. 72(10):1322-32. [Medline].

Fournier JC, DeRubeis RJ, Hollon ST, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. [Full Text].

Hopko DR, Lejuez CW, Ruggiero KJ, Eifert GH. Contemporary behavioral activation treatments for depression: procedures, principles, and progress. Clin Psychol Rev. 2003 Oct. 23(5):699-717. [Medline].

Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK, et al. A component analysis of cognitive-behavioral treatment for depression. J Consult Clin Psychol. 1996 Apr. 64(2):295-304. [Medline].

Kanter JW, Manos RC, Bowe WM, Baruch DE, Busch AM, Rusch LC. What is behavioral activation? A review of the empirical literature. Clin Psychol Rev. 2010 Aug. 30(6):608-20. [Medline].

Lejuez CW, Hopko DR, Hopko SD. A brief behavioral activation treatment for depression. Treatment manual. Behav Modif. 2001 Apr. 25(2):255-86. [Medline].

Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006 Aug. 74(4):658-70. [Medline].

McCauley, E., Schloredt, K., Gudmundsen, G., et al. Expanding behavioral activation to depressed adolescents: Lessons learned in treatment development. Cogn and Behav Pract. 2011. 18, 371-383.

Meeks S, Looney SW, Van Haitsma K, Teri L. BE-ACTIV: a staff-assisted behavioral intervention for depression in nursing homes. Gerontologist. 2008 Feb. 48(1):105-14. [Medline].

Sood, J. R., Cisek, E., Zimmerman, J., et al. Treatment of depressive symptoms during short-term rehabilitation: an attempted replication of the DOUR project. Rehabil Psychol. 2003. 48, 44-49.

Quijano, L. M., Stanley, M. A., Peterson, N. J., et al. Healthy Ideas: a depression intervention delivered by community-based case managers serving older adults. J Appl Gerontol. 2007. 26:139-156.

Young JE, Weinberger AD, Beck, AT. Cognitive therapy for depression. Barlow D.H. Clinical handbook of psychological disorders: A step-by-step treatment manual. Third Edition. New York: Guilford Press; 2001. 264-308.

Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: Guilford Press; 1979.

Areán PA, Cook BL. Psychotherapy and combined psychotherapy/pharmacotherapy for late life depression. Biol Psychiatry. 2002 Aug 1. 52(3):293-303. [Medline].

Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry. 2006 Sep. 163(9):1493-501. [Medline].Klerman, G. L., Weissman, M. M., Rounsaville, B. J., et al. Interpersonal Psychotherapy of Depression. New York: Basic Books; 1984.

Gillies, L. A. Interpersonal psychotherapy for depression and other disorders. Barlow D.H. Clinical Handbook of Psychological Disoders: A Step-by-Step Treatment Manual. 3rd ed. New York: The Guilford Press; 2001.

Mufson L, Fairbanks J. Interpersonal psychotherapy for depressed adolescents: a one-year naturalistic follow-up study. J Am Acad Child Adolesc Psychiatry. 1996 Sep. 35(9):1145-55. [Medline].

Reynolds CF 3rd, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999 Jan 6. 281(1):39-45. [Medline].

Kabat-Zinn, J. Full Catastrophe Living: The program of the Stress Reduction Clinic at the University of Massachusetts Medical Center. New York: Delta; 1990.

Segal, Z. V., Teasdale, J. D., & Williams, J. M. G. Mindfulness-based cognitive therapy: Theoretical rationale and empirical status. Hayes, S.C., Follette, V.M. and Linehan, M.M. Mindfulness and Acceptance: Expanding the Cognitive-Behavioral Tradition. New York: Guilford Press; 2011.

Segal, Z. V., Williams, J. M. G., & Teasdale, J. D. Mindfulness based cognitive therapy for depression: A new approach to preventing relapse. New York: Guilford Press; 2002.

Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol. 2000 Aug. 68(4):615-23. [Medline].

Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol. 2004 Feb. 72(1):31-40. [Medline].

Kuyken W, Warren FC, Taylor RS, Whalley B, Crane C, Bondolfi G, et al. Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse: An Individual Patient Data Meta-analysis From Randomized Trials. JAMA Psychiatry. 2016 Apr 27. [Medline].

Nezu, A. M., Nezu, C. M., & D’Zurilla, T. J. Solving life’s problems: A 5-step guide to enhanced well-being. New York: Springer; 2007.

Nezu AM, Ronan GF. Life stress, current problems, problem solving, and depressive symptoms: an integrative model. J Consult Clin Psychol. 1985 Oct. 53(5):693-7. [Medline].

Nezu, A. M., Nezu, C. M., Saraydarian, L., et al. Social problem solving as a moderator variable between negative life stress and depressive symptoms. Cognitive Ther Res. 1986. 10:489-498.

Nezu, A. M. Problem solving and behavior therapy revisited. Behav Ther. 2004. 35:1-33.

D’Zurilla, T. J. & Nezu, A. M. Problem-solving therapy: A positive approach to clinical intervention. 3rd ed. New York: Springer; 2007.

D’Zurilla, T. J., Nezu, A. M., & Maydeu-Olivares, A. Social problem solving: Theory and assessment. Chang, E.C., D’Zurilla, T.J., & Sanna, L.J. Social problem solving: Theory, research, and training. Washington, DC: American Psychological Association; 2004. 11-27.

Nezu, A. M., Nezu, C. M., & Lombardo, E. Problem-solving therapy. O’Donohue, W., Fisher, J. E. & Hayes, S. C.,. Cognitive behavior therapy: Applying empirically supported techniques in your practice. Hoboken, NJ: John Wiley & Sons; 2003. 301-307.

Nezu AM. Efficacy of a social problem-solving therapy approach for unipolar depression. J Consult Clin Psychol. 1986 Apr. 54(2):196-202. [Medline].

Nezu AM, Perri MG. Social problem-solving therapy for unipolar depression: an initial dismantling investigation. J Consult Clin Psychol. 1989 Jun. 57(3):408-13. [Medline].

Arean PA, Perri MG, Nezu AM, Schein RL, Christopher F, Joseph TX. Comparative effectiveness of social problem-solving therapy and reminiscence therapy as treatments for depression in older adults. J Consult Clin Psychol. 1993 Dec. 61(6):1003-10. [Medline].

Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ. 1995 Feb 18. 310(6977):441-5. [Medline][Full Text].

Dowrick C, Dunn G, Ayuso-Mateos JL, Dalgard OS, Page H, Lehtinen V, et al. Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial. Outcomes of Depression International Network (ODIN) Group. BMJ. 2000 Dec 9. 321(7274):1450-4. [Medline][Full Text].

Lam RW, Levitt AJ, Levitan RD, Michalak EE, Morehouse R, Ramasubbu R, et al. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015 Nov 18. 1-9. [Medline].

Lieverse R, Van Someren EJ, Nielen MM, Uitdehaag BM, Smit JH, Hoogendijk WJ. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. Arch Gen Psychiatry. 2011 Jan. 68(1):61-70. [Medline].

Wirz-Justice A, Bader A, Frisch U, Stieglitz RD, Alder J, Bitzer J, et al. A randomized, double-blind, placebo-controlled study of light therapy for antepartum depression. J Clin Psychiatry. 2011 Jul. 72(7):986-93. [Medline].

Cassels C. FDA Clears TMS Device for Resistant Depression. Medscape Medical News. Jan 9 2013. [Full Text].

Krogh J, Nordentoft M, Sterne JA, Lawlor DA. The effect of exercise in clinically depressed adults: systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2011 Apr. 72(4):529-38. [Medline].

Kennedy SH, Giacobbe P, Rizvi SJ, et al. Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry. 2011 May. 168(5):502-10. [Medline].

Brunoni AR, Valiengo L, Baccaro A, Zanão TA, de Oliveira JF, Goulart A, et al. The Sertraline vs Electrical Current Therapy for Treating Depression Clinical Study: Results From a Factorial, Randomized, Controlled Trial. JAMA Psychiatry. 2013 Feb 6. 1-9. [Medline].

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov. 163(11):1905-17. [Medline].

Rush AJ. Star-D: lessons learned and future implications. Depress Anxiety. 2011 Jul. 28(7):521-4. [Medline].

Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007 Jun. 68(6):843-53. [Medline].

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008 Apr. 28(2):156-65. [Medline].

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009 Apr. 14(4):197-206. [Medline].

Lowry F. Vagus nerve stimulation effective in resistant depression. Medscape Medical News. May 16, 2013. [Full Text].

Conway CR, Chibnall JT, Gebara MA, Price JL, Snyder AZ, Mintun MA, et al. Association of cerebral metabolic activity changes with vagus nerve stimulation antidepressant response in treatment-resistant depression. Brain Stimul. 2013 Feb 13. [Medline].

Cassels C. TMS for resistant depression: long-term results are in. Medscape Medical News. May 24, 2013. [Full Text].

March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007 Oct. 64(10):1132-43. [Medline].

Hughes CW, Emslie GJ, Crismon ML, Posner K, Birmaher B, Ryan N, et al. Texas Children’s Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jun. 46(6):667-86. [Medline].

Brent DA. The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step. Depress Anxiety. 2009. 26(10):871-4. [Medline].

Leonard HL, March J, Rickler KC, Allen AJ. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997 Jun. 36(6):725-36. [Medline].

Rey-Sánchez F, Gutiérrez-Casares JR. Paroxetine in children with major depressive disorder: an open trial. J Am Acad Child Adolesc Psychiatry. 1997 Oct. 36(10):1443-7. [Medline].

Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry. 2008 Jul. 193(1):10-7. [Medline].

Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997 Nov. 54(11):1031-7. [Medline].

March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007 Oct. 64(10):1132-43. [Medline].

Cassels C. FDA Suicide Warnings Change Antidepressant Prescribing Patterns, but Physicians Ignore Monitoring Recommendations. Medscape Today. Available at http://www.medscape.com/viewarticle/715952. Accessed: March 22, 2010.

Cassels C. FDA Suicide Warnings About Antidepressants Cut Rates of Depression Diagnosis and Treatment. Medscape Today. Available at http://www.medscape.com/viewarticle/704235. Accessed: March 22, 2010.

Leon AC, Solomon DA, Li C, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry. 2011 May. 72(5):580-6. [Medline].

Carlsten A, Waern M, Ekedahl A, Ranstam J. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. 2001 Oct-Nov. 10(6):525-30. [Medline].

Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ. 2003 May 10. 326(7397):1008. [Medline][Full Text].

Olfson M, Marcus SC, Druss B, Pincus HA. National trends in the use of outpatient psychotherapy. Am J Psychiatry. 2002 Nov. 159(11):1914-20. [Medline].

March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004 Aug 18. 292(7):807-20. [Medline].

Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006 Jan. 163(1):41-7. [Medline].

Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010 Oct. 67(10):1012-24. [Medline].

Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med.2006 Feb 9. 354(6):579-87. [Medline][Full Text].

Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry. 2012 Feb. 169(2):134-40. [Medline].

FDA drug safety communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. US Food and Drug Administration. Available at http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm. Accessed: December 14, 2011.

Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006 Feb. 160(2):173-6. [Medline].

di Scalea TL, Wisner KL. Pharmacotherapy of postpartum depression. Expert Opin Pharmacother. 2009 Nov. 10(16):2593-607. [Medline][Full Text].

Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009 Sep. 114(3):703-13. [Medline].

Wisner KL, Perel JM, Peindl KS, Hanusa BH, Piontek CM, Findling RL. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry. 2004 Jul. 161(7):1290-2. [Medline].

Weissman AM, Levy BT, Hartz AJ, Bentler S, Donohue M, Ellingrod VL, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry. 2004 Jun. 161(6):1066-78. [Medline].

Andreescu C, Lenze EJ, Mulsant BH, Wetherell JL, Begley AE, Mazumdar S, et al. High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression. Depress Anxiety. 2009. 26(3):266-72. [Medline][Full Text].

Cooper C, Katona C, Lyketsos K, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011 Jul. 168(7):681-8. [Medline].

Fabian TJ, Amico JA, Kroboth PD, Mulsant BH, Corey SE, Begley AE, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med. 2004 Feb 9. 164(3):327-32. [Medline].

King RA, Segman RH, Anderson GM. Serotonin and suicidality: the impact of acute fluoxetine administration. I: Serotonin and suicide. Isr J Psychiatry Relat Sci. 1994. 31(4):271-9. [Medline].

Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf. 1993 Mar. 8(3):186-212. [Medline].

Pan A, Okereke OI, Sun Q, Logroscino G, Manson JE, Willett WC, et al. Depression and incident stroke in women. Stroke. 2011 Oct. 42(10):2770-5. [Medline][Full Text].

Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA. 2011 Sep 21. 306(11):1241-9. [Medline][Full Text].

Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010 Aug. 167(8):934-41. [Medline].

Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009 Sep. 166(9):980-91. [Medline].

Gilbody S, Bower P, Fletcher J, Richards D, Sutton AJ. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch Intern Med. 2006 Nov 27. 166(21):2314-21. [Medline].

Kroll L, Harrington R, Jayson D, Fraser J, Gowers S. Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients. J Am Acad Child Adolesc Psychiatry. 1996 Sep. 35(9):1156-61. [Medline].

A Message From APA President Dilip Jeste, M.D., on DSM-5. Available at http://www.psychnews.org/files/DSM-message.pdf. Accessed: December 1, 2012.

Anderson P. Stimulation device shows ‘immediate’ impact on depression. Medscape Medical News. July 31, 2014. [Full Text].

Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013 Mar. 74(3):242-8. [Medline].

Bender K. Cognitive therapy, meds equal in curbing depression relapse. Medscape Medical News. November 20, 2013. [Full Text].

Brauser D. Depression Causally Linked to Heart Disease. Medscape Medical News. Available at http://www.medscape.com/viewarticle/820313. Accessed: February 12, 2014.

Brunner EJ, Shipley MJ, Britton AR, Stansfeld SA, Heuschmann PU, Rudd AG, et al. Depressive disorder, coronary heart disease, and stroke: dose-response and reverse causation effects in the Whitehall II cohort study. Eur J Prev Cardiol. 2014 Feb 3. [Medline].

Cassels C. FDA Approves New SNRI for Major Depression. Medscape Medical News. Available at http://www.medscape.com/viewarticle/808481.. Accessed: August 6, 2013.

Cassels C. FDA Approves Vortioxetine for Major Depression. Medscape Medical News. Available at http://www.medscape.com/viewarticle/811892. Accessed: October 8, 2013.

Dennis CL, Dowswell T. Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database Syst Rev. 2013 Feb 28. 2:CD001134. [Medline].

Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry. 1997 Mar. 170:205-28. [Medline].

Hollon SD, Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. Depress Anxiety. 2010 Oct. 27(10):891-932. [Medline][Full Text].

Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, et al. Varicella Zoster Virus-Specific Immune Responses to a Herpes Zoster Vaccine in Elderly Recipients With Major Depression and the Impact of Antidepressant Medications. Clin Infect Dis. 2013 Feb 13. [Medline].

Jarrett RB, Minhajuddin A, Gershenfeld H, Friedman ES, Thase ME. Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. JAMA Psychiatry. 2013 Nov 1. 70(11):1152-60. [Medline].

Rohan ML, Yamamoto RT, Ravichandran CT, et al. Rapid mood-elevating effects of low fieldmagnetic stimulation in depression. Biol Psychiatry. 2014 Aug 1. 76(3):186-93. [Medline].

Steingard RJ, Renshaw PF, Yurgelun-Todd D, Appelmans KE, Lyoo IK, Shorrock KL, et al. Structural abnormalities in brain magnetic resonance images of depressed children. J Am Acad Child Adolesc Psychiatry. 1996 Mar. 35(3):307-11. [Medline].